<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1186/s12951-022-01555-x</query><apiKey>87ba7cb21f89ce78154df796840621f4</apiKey><result><total>1</total><start>1</start><pageLength>2</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="research-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="publisher-id">12951</journal-id><journal-title-group><journal-title>Journal of Nanobiotechnology</journal-title><abbrev-journal-title abbrev-type="publisher">J Nanobiotechnol</abbrev-journal-title></journal-title-group><issn pub-type="epub">1477-3155</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s12951-022-01555-x</article-id><article-id pub-id-type="manuscript">1555</article-id><article-id pub-id-type="doi">10.1186/s12951-022-01555-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Hyaluronic acid-coated Bi:Cu<sub>2</sub>O: an H<sub>2</sub>S-responsive agent for colon cancer with targeted delivery and enhanced photothermal performance</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><name><surname>Cheng</surname><given-names>Yuying</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Bo</surname><given-names>Haiji</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au3"><name><surname>Qin</surname><given-names>Ruomeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au4"><name><surname>Chen</surname><given-names>Fulai</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au5"><name><surname>Xue</surname><given-names>Fengfeng</given-names></name><address><email>Xueff@sumhs.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1295102201555x_cor5">e</xref></contrib><contrib contrib-type="author" id="Au6"><name><surname>An</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au7"><name><surname>Huang</surname><given-names>Gang</given-names></name><address><email>huangg@sumhs.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1295102201555x_cor7">g</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au8"><name><surname>Tian</surname><given-names>Qiwei</given-names></name><address><email>tianqw@sumhs.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs1295102201555x_cor8">h</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.507037.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1764 1277</institution-id><institution content-type="org-division">Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital</institution><institution content-type="org-name">Shanghai University of Medicine and Health Sciences</institution></institution-wrap><addr-line content-type="postcode">201318</addr-line><addr-line content-type="city">Shanghai</addr-line><country country="CN">China</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution content-type="org-division">Department of Pathology</institution><institution content-type="org-name">Naval Medical Center of PLA</institution></institution-wrap><addr-line content-type="street">No. 338 Huaihai West Road</addr-line><addr-line content-type="postcode">200052</addr-line><addr-line content-type="city">Shanghai</addr-line><country country="CN">China</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.412531.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0701 1077</institution-id><institution content-type="org-division">Shanghai Municipal Education Committee Key Laboratory of Molecular Imaging Probes and Sensors</institution><institution content-type="org-name">Shanghai Normal University</institution></institution-wrap><addr-line content-type="postcode">200234</addr-line><addr-line content-type="city">Shanghai</addr-line><country country="CN">China</country></aff></contrib-group><author-notes><fn fn-type="con"><p>Yuying Cheng and Haiji Bo are contributed equally to this work</p></fn><corresp id="IDs1295102201555x_cor5"><label>e</label><email>Xueff@sumhs.edu.cn</email></corresp><corresp id="IDs1295102201555x_cor7"><label>g</label><email>huangg@sumhs.edu.cn</email></corresp><corresp id="IDs1295102201555x_cor8"><label>h</label><email>tianqw@sumhs.edu.cn</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>7</month><year>2022</year></pub-date><pub-date date-type="collection" publication-format="electronic"><month>12</month><year>2022</year></pub-date><volume>20</volume><issue seq="347">1</issue><elocation-id>346</elocation-id><history><date date-type="registration"><day>13</day><month>7</month><year>2022</year></date><date date-type="received"><day>27</day><month>4</month><year>2022</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2022</year></date><date date-type="online"><day>26</day><month>7</month><year>2022</year></date></history><permissions><copyright-statement content-type="compact">© The Author(s) 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link xlink:href="http://creativecommons.org/publicdomain/zero/1.0/" ext-link-type="uri">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract xml:lang="en" id="Abs1"><title>Abstract</title><sec id="ASec1"><title>Background</title><p id="Par1">Endogenous hydrogen sulfide (H<sub>2</sub>S)-responsive theranostic agents have attracted extensive attention due to their specificity for colon cancer. However, the development of such agents with high enrichment in tumors and excellent photothermal performance remains challenging.</p></sec><sec id="ASec2"><title>Results</title><p id="Par2">We prepared hyaluronic acid (HA)-coated Bi-doped cuprous oxide (Bi:Cu<sub>2</sub>O@HA) via a one-pot method. The HA specifically targets colon cancer tumor cells to improve the enrichment of Bi:Cu<sub>2</sub>O@HA at tumor sites, while the doped Bi both enhances the photothermal performance of the H<sub>2</sub>S-triggered Cu<sub>2</sub>O and serves as an agent for tumor imaging. The results in this work demonstrated that the Bi:Cu<sub>2</sub>O@HA nanoparticles exhibit good biocompatibility, target colon cancer tumor cells, facilitate computed tomography imaging, and enhanced H<sub>2</sub>S-responsive photothermal therapy performance, resulting in an excellent therapeutic effect in colon cancer.</p></sec><sec id="ASec3"><title>Conclusions</title><p id="Par3">The novel Bi:Cu<sub>2</sub>O@HA nanoparticles exhibit excellent tumor targeting and photothermal therapeutic effects, which provide new strategies and insights for colon cancer therapy.</p></sec><sec id="ASec4"><title>Graphical Abstract</title><p id="Par4"><fig id="Figa" position="anchor"><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Figa_HTML.png" position="anchor" id="MO1"/></fig></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cu<sub>2</sub>O</kwd><kwd>Endogenous hydrogen sulfide</kwd><kwd>CT imaging</kwd><kwd>Photothermal therapy</kwd><kwd>Colon cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>the Key Program of National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">81830052</award-id></award-group><award-group><funding-source><institution-wrap><institution>Construction project of Shanghai Key Laboratory of Molecular Imaging</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">18DZ2260400</award-id></award-group><award-group><funding-source><institution-wrap><institution>Natural Science Foundation of Shanghai</institution><institution-id institution-id-type="doi" vocab="open-funder-registry">http://dx.doi.org/10.13039/100007219</institution-id></institution-wrap></funding-source><award-id award-type="FundRef grant">20ZR1472300</award-id></award-group><award-group><funding-source><institution-wrap><institution>Foundation of National Infrastructures for Translational Medicine</institution></institution-wrap></funding-source><award-id award-type="FundRef grant">Shanghai, TMSK-2021-131</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>BioMed Central</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>347</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2022</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>The Author(s)</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2022</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2022</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>7</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>13</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>ArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/12951_2022_Article_1555.pdf</meta-value></custom-meta><custom-meta><meta-name>pdf-type</meta-name><meta-value>Typeset</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>OriginalPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Chemistry</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Biotechnology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Nanotechnology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Molecular Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Chemistry and Materials Science</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="ESMHint"><title>Supplementary Information</title><p>The online version contains supplementary material available at <ext-link xlink:href="10.1186/s12951-022-01555-x" ext-link-type="doi">https://doi.org/10.1186/s12951-022-01555-x</ext-link>.</p></notes></front><body><sec id="Sec1"><title>Background</title><p id="Par5">Theranostic agents that are responsive to the tumor environment have attracted considerable attention in diagnosis and treatment due to their ability to target tumor tissues [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. The tumor microenvironment in colon cancer is characterized by the presence of endogenous hydrogen sulfide (H<sub>2</sub>S) [<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR9">9</xref>]. Thus, H<sub>2</sub>S can serve as a trigger for colon cancer-targeting theranostic agents. For example, endogenous H<sub>2</sub>S-triggered BODIPY, MOF, and Cu<sub>2</sub>O theranostic agents have been developed for photoacoustic (PA) and near-infrared (NIR) fluorescence imaging along with photothermal and photodynamic therapy for colon cancer [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>]. However, the enrichment of these agents in tumors depends primarily on the enhanced permeability and retention effect rather than targeted delivery, and their NIR absorption requires further improvement [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, it remains challenging to develop H<sub>2</sub>S-triggered theranostic agents with strong NIR absorption and targeted tumor delivery.</p><p id="Par6">Bismuth (Bi)-based nanoparticles (NPs) are widely used as computed tomography (CT) agents due to their good biocompatibility and X-ray attenuation properties [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR17">17</xref>]. Bismuth sulfide (Bi<sub>2</sub>S<sub>3</sub>) is a narrow-bandgap semiconductor with strong absorption throughout the NIR region [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, Bi<sub>2</sub>S<sub>3</sub> is widely used in combination with other semiconductors to enhance the absorption [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. For example, the absorption of the Cu<sub>2</sub>O/Bi<sub>2</sub>S<sub>3</sub> heterojunction is obviously stronger than that of either Cu<sub>2</sub>O or Bi<sub>2</sub>S<sub>3</sub> alone, especially in the NIR region [<xref ref-type="bibr" rid="CR24">24</xref>]. Thus, doping with Bi is an effective way to enhance the NIR absorption of endogenous H<sub>2</sub>S-triggered Cu<sub>2</sub>O. However, to the best of our knowledge, little information on this topic is available in the literature.</p><p id="Par7">Hyaluronic acid (HA), a polysaccharide, can target the CD44 receptors that are highly expressed on the surfaces of colon cancer tumor cells [<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR28">28</xref>]. Thus, HA is widely used for targeted drug delivery in colon cancer [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR31">31</xref>]. In addition, HA contains abundant carboxyl groups and can act as a surfactant to regulate the synthesis of nanomaterials [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Thus, HA can be applied in the one-step synthesis of nanomaterials for targeted tumor delivery. For example, Fu and coworkers developed a one-pot method to prepare MnWO<sub>4</sub> using HA as a surfactant [<xref ref-type="bibr" rid="CR34">34</xref>]. The obtained MnWO<sub>4</sub> NPs exhibited good biocompatibility and tumor-targeting ability. Therefore, HA may be a good surfactant to develop an H<sub>2</sub>S-triggered Bi-doped Cu<sub>2</sub>O theranostic agent with strong NIR absorption and tumor-targeting delivery.</p><p id="Par8">As a proof of concept, we constructed a smart H<sub>2</sub>S-responsive nanoplatform: HA-modified Bi-doped cuprous oxide (Cu<sub>2</sub>O) NPs (Bi:Cu<sub>2</sub>O@HA NPs). As shown in Scheme <xref rid="Sch1" ref-type="fig">1</xref>, the NPs combine tumor-targeted delivery, high-performance CT imaging, and enhanced photothermal therapy (PTT) into one nanoprobe for the theranostic treatment of colon cancer. The HA not only acts as a surfactant to prepare the NPs, it also improves the tumor-targeting ability of the NPs [<xref ref-type="bibr" rid="CR35">35</xref>]. Similarly, Bi both improves the CT imaging performance of the NPs and enhances the absorption of Cu<sub>2</sub>O. Thus, the endogenous H<sub>2</sub>S-triggered PTT effect of Cu<sub>2</sub>O can be enhanced by both HA and Bi. This intelligent reagent with tumor-targeted delivery and enhanced theranostic effect opens up a new avenue for developing H<sub>2</sub>S-triggered theranostic agents.</p><p id="Par9"><fig id="Sch1"><label>Scheme 1</label><caption xml:lang="en"><p>Schematic diagram of the synthesis of multifunctional Bi:Cu<sub>2</sub>O@HA NPs and their application in colon cancer-targeted delivery, CT imaging, and enhanced H<sub>2</sub>S-responsive PTT</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Sch1_HTML.png"/></fig></p></sec><sec id="Sec2"><title>Results and discussion</title><sec id="Sec3"><title>Preparation and characterization of Bi:Cu<sub>2</sub>O@HA NPs</title><p id="Par10">The Bi:Cu<sub>2</sub>O@HA NPs were prepared through a one-pot method. After centrifugal purification, the crystalline structure, morphology, composition, and hydrodynamic size of the obtained Bi:Cu<sub>2</sub>O@HA NPs were characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), elemental mapping, Fourier transform infrared (FT-IR) spectroscopy, and dynamic light scattering (DLS). The diffraction peaks of the obtained Bi:Cu<sub>2</sub>O@HA NPs at 36.2, 42.5, and 61.6 degrees are well matched with the (111), (200), and (220) crystal faces of cubic Cu<sub>2</sub>O (JCPDS card NO:77–0199, Fig. <xref rid="Fig1" ref-type="fig">1</xref>A), respectively, indicating that the obtained NPs were cubic crystals. As shown in the SEM image (Fig. <xref rid="Fig1" ref-type="fig">1</xref>B), the Bi:Cu<sub>2</sub>O@HA NPs had uniform spherical morphologies with particle sizes of approximately 63.09 nm (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S1).</p><p id="Par11"><fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>Characterization of Bi:Cu<sub>2</sub>O@HA NPs. <bold>A</bold> XRD pattern (red line). <bold>B</bold> SEM image. <bold>C</bold> TEM image and elemental mapping images. <bold>D</bold> FT-IR spectrum (red line). <bold>E</bold> DLS size distribution of the prepared Bi:Cu<sub>2</sub>O@HA NPs. The blue lines in <bold>A</bold> are the diffraction peaks of cubic Cu<sub>2</sub>O (JCPDS card NO:77–0199). The blue line in <bold>D</bold> is the FT-IR spectrum of HA</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig1_HTML.png"/></fig></p><p id="Par12">The elemental mapping image (Fig. <xref rid="Fig1" ref-type="fig">1</xref>C) demonstrates that Bi, Cu, and O were uniformly distributed in each NP, indicating that Bi was homogeneously doped in the cubic Cu<sub>2</sub>O structure. The X-ray photoelectron spectroscopy (XPS) and energy-dispersive X-ray spectrometry (EDX) results further demonstrated the existence of Bi in the obtained NPs (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figures S2 and S3). As shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>D, the FT-IR spectrum of HA showed a peak corresponding to the C–H single bond at 2882 cm<sup>− 1</sup> and a typical amide peak at 1655 cm<sup>− 1</sup> [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. These two peaks were retained in the spectrum of Bi:Cu<sub>2</sub>O@HA, indicated that HA was successfully loaded onto the NPs. Furthermore, the zeta potential of Cu<sub>2</sub>O@HA and Bi:Cu<sub>2</sub>O@HA NPs informed the coating of HA on the surface of the obtained NPs (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S4). The hydrodynamic size of the Bi:Cu<sub>2</sub>O@HA NPs determined by DLS was 130.9 nm, much larger than the sizes measured by SEM and TEM (Fig. <xref rid="Fig1" ref-type="fig">1</xref>E). This may be due to the strong hydrophilicity of HA. These characterization results demonstrate that hydrophilic Bi:Cu<sub>2</sub>O@HA NPs were successfully prepared. Subsequently, the size and polydispersity index (PDI) changes of Bi:Cu<sub>2</sub>O@HA NPs were studied in water, PBS and serum, respectively (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S5). According to the results, the hydrodynamic diameter did not change significantly within a week, indicating that Bi:Cu<sub>2</sub>O@HA NPs has good dispersion stability.</p></sec><sec id="Sec4"><title>H<sub>2</sub>S-responsive performance</title><p id="Par13">To explore the H<sub>2</sub>S-responsive performance of the Bi:Cu<sub>2</sub>O@HA NPs, NaHS was used to simulate endogenous H<sub>2</sub>S (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A), and Cu<sub>2</sub>O@HA NPs prepared using the same method as the Bi:Cu<sub>2</sub>O@HA NPs but without Bi doping were used as a control (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figures S6–S9). The crystal structure, morphology, absorption, and photothermal performance after reaction with NaHS were investigated. The SEM image in Fig. <xref rid="Fig2" ref-type="fig">2</xref>B shows that after reaction with NaHS, the Bi:Cu<sub>2</sub>O@HA NPs exhibited a spherical morphology with an average diameter of approximately 65 nm, slightly larger than the diameter of the initial Bi:Cu<sub>2</sub>O@HA NPs, in agreement with a previous report [<xref ref-type="bibr" rid="CR38">38</xref>]. In addition, the XRD peaks of the Bi:Cu<sub>2</sub>O@HA NPs after reaction with NaHS at 31.5, 49.5, and 59.4 degrees were well matched with the (103), (110), and (116) crystal faces of hexagonal CuS (JCPDS card NO: 99 − 0037, Fig. <xref rid="Fig2" ref-type="fig">2</xref>C), respectively, indicating the formation of CuS.</p><p id="Par14"><fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><p>H<sub>2</sub>S-responsive performance of the Bi:Cu<sub>2</sub>O@HA NPs. <bold>A</bold> Schematic diagram of the reaction of Bi:Cu<sub>2</sub>O@HA NPs with NaHS. <bold>B</bold> SEM image. <bold>C </bold>XRD pattern of Bi:Cu<sub>2</sub>O@HA after reaction with NaHS. <bold>D</bold> Absorption of Cu<sub>2</sub>O@HA and Bi:Cu<sub>2</sub>O@HA NPs before and after reaction with NaHS. <bold>E</bold> Plots of Δ<italic>T</italic> vs. time for Cu<sub>2</sub>O@HA + NaHS and Bi:Cu<sub>2</sub>O@HA + NaHS under 808-nm laser irradiation (1 W/cm<sup>2</sup>). <bold>F</bold> Plots of Δ<italic>T</italic> vs. time for Bi:Cu<sub>2</sub>O@HA (0.5 mM) + NaHS (4 mM) during six cycles of irradiation (1 W/cm<sup>2</sup>)</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig2_HTML.png"/></fig></p><p id="Par15">To investigate whether doping with Bi enhanced the NIR absorption of Cu<sub>2</sub>O, we measured the absorption of the Cu<sub>2</sub>O@HA and Bi:Cu<sub>2</sub>O@HA NPs before and after reaction with NaHS. As shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>D, both the Cu<sub>2</sub>O@HA and Bi:Cu<sub>2</sub>O@HA NPs exhibited stronger absorption in the NIR region after reaction with NaHS compared with before reaction. Notably, the NIR absorption, especially at the laser wavelength of 808 nm (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S10A, B), of Bi-doped Cu<sub>2</sub>O@HA after reaction with NaHS was slightly improved compared with that of Cu<sub>2</sub>O@HA, indicating that doping with Bi has the potential to enhance the photothermal performance of Cu<sub>2</sub>O exposed to H<sub>2</sub>S. The photothermal performances of the Cu<sub>2</sub>O@HA and Bi:Cu<sub>2</sub>O@HA after reaction with NaHS were compared based on the temperature changes (Δ<italic>T</italic>) of dispersions of the NPs in water under irradiation by an 808-nm laser. As shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>E, the Δ<italic>T</italic> values of Cu<sub>2</sub>O@HA and Bi:Cu<sub>2</sub>O@HA respectively increased by 13.2 and 16.5 °C after reaction with NaHS, suggesting that the photothermal performance of Cu<sub>2</sub>O@HA was improved by doping with Bi. The Δ<italic>T</italic> of Bi:Cu<sub>2</sub>O@HA explored by different dispersion concentration and laser power density further suggests the good performance (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S11A–D). The photothermal conversion efficiency also increased slightly compared to the previously reported efficiency for Cu<sub>2</sub>O (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S12A, B) [<xref ref-type="bibr" rid="CR12">12</xref>]. Furthermore, after six irradiation and cooling cycles (Fig. <xref rid="Fig2" ref-type="fig">2</xref>F), the maximum Δ<italic>T</italic> of the Bi:Cu<sub>2</sub>O@HA dispersion after reaction with NaHS hardly changed, indicating the good photothermal stability of Bi:CuS@HA. The above results indicate that Bi doping is an effective strategy to enhance the photothermal performance of H<sub>2</sub>S-responsive Cu<sub>2</sub>O@HA NPs.</p></sec><sec id="Sec5"><title>CT imaging and tumor-targeting performance</title><p id="Par16">Considering the good X-ray attenuation properties, the CT imaging performance of the Bi:Cu<sub>2</sub>O@HA NPs was investigated using the commercial Iohexol CT contrast agent as a control. As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>A, as the concentrations of Iohexol and Bi:Cu<sub>2</sub>O@HA increased, the CT images of both agents became brighter, indicating a gradual increase in the CT signals. Furthermore, the CT imaging performance of the Bi:Cu<sub>2</sub>O@HA NPs was superior to that of Iohexol at the same concentration. The linear correlations between the CT signals and the concentrations of Iohexol and Bi:Cu<sub>2</sub>O@HA further demonstrate that the CT imaging performance of Bi:Cu<sub>2</sub>O@HA NPs was better than that of Iohexol at the same concentration (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B). The above results suggest that Bi:Cu<sub>2</sub>O@HA NPs can be used as an agent for CT imaging.</p><p id="Par17"><fig id="Fig3"><label>Fig. 3</label><caption xml:lang="en"><p> <bold>A</bold>, <bold>B</bold> In vitro CT images and corresponding linear correlations of the CT signals with the concentrations of Bi:Cu<sub>2</sub>O@HA NP and Iohexol. <bold>C</bold> In vitro CT images (inset) and corresponding plots of the CT signals vs. concentration for CT26 cells in the Bi:Cu<sub>2</sub>O@HA and block groups. <bold>D</bold>, <bold>E</bold> In vivo CT images and corresponding CT values at the tumor sites of tumor-bearing mice after injection in the Bi:Cu<sub>2</sub>O@HA and block groups. Data are presented as means ± SDs (n = 3). *p &lt; 0.1, **p &lt; 0.01, ***p &lt; 0.001</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig3_HTML.png"/></fig></p><p id="Par18">Based on the good CT imaging performance and the ability of HA to target the highly expressed CT44 receptors on the surfaces of colon cancer cells, the targeting ability of the Bi:Cu<sub>2</sub>O@HA NPs was explored both in vitro and in vivo using CT imaging. Two groups of experiments were established: one with the Bi:Cu<sub>2</sub>O@HA group and another with a block group. As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>C, the CT image of the CT26 colon cancer cells after incubation with Bi:Cu<sub>2</sub>O@HA was brighter than that of the block group at the same concentration (inset of Fig. <xref rid="Fig3" ref-type="fig">3</xref>C). The corresponding signal of the Bi:Cu<sub>2</sub>O@HA group was also much stronger than that of the block group, suggesting that HA significantly enhanced the tumor cell targeting ability. The CT images of tumor-bearing mice were collected after the intravenous injection of Bi:Cu<sub>2</sub>O@HA to evaluate the tumor-targeting performance in vivo.</p><p id="Par19">As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>D, the colors of the CT images at the tumor sites (red circles) before injection were similar in the Bi:Cu<sub>2</sub>O@HA and block groups. After intravenous administration, the tumor sites in the CT images of the mice in the Bi:Cu<sub>2</sub>O@HA group gradually became brighter and reached maximum brightness at 8 h after injection. In comparison, the tumor sites in the CT images of mice in the block group were darker at the same time points. The corresponding signals at the tumor sites were much higher in the Bi:Cu<sub>2</sub>O@HA group than in the block group (Fig. <xref rid="Fig3" ref-type="fig">3</xref>E). These results further indicate that the Bi:Cu<sub>2</sub>O@HA NPs exhibited good targeting performance for colon cancer in vivo since HA can target the expressed receptors on cancer.</p></sec><sec id="Sec6"><title>Biocompatibility</title><p id="Par20">Cytotoxicity, hemolysis, and routine blood biochemical index analyses were performed to investigate the biocompatibility of the Bi:Cu<sub>2</sub>O@HA NPs. First, the cytotoxicity of the Bi:Cu<sub>2</sub>O@HA NPs was assessed in human umbilical vein endothelial cells (HUVECs) and mouse colon cancer CT26 cells by MTT assay. The cell survival rates of both the HUVEC and CT26 cells were more than 80%, even at a concentration of 80 µg/mL (Fig. <xref rid="Fig4" ref-type="fig">4</xref>A, B), indicating that the Bi:Cu<sub>2</sub>O@HA NPs had low cytotoxicity. Compared to water (positive control), the Bi:Cu<sub>2</sub>O@HA NPs did not cause significant damage to the erythrocyte membranes (Fig. <xref rid="Fig4" ref-type="fig">4</xref>C), similar to the PBS group (negative control). More importantly, the routine blood indexes of the mice after the tail vein injection of Bi:Cu<sub>2</sub>O@HA NPs for 36 h were not significantly different than those of mice in the control group, indicating the good biocompatibility of Bi:Cu<sub>2</sub>O@HA NPs in vivo (Fig. <xref rid="Fig4" ref-type="fig">4</xref>D). These results demonstrate that the Bi:Cu<sub>2</sub>O@HA NPs exhibited good biocompatibility and great potential for further application in vivo.</p><p id="Par21"><fig id="Fig4"><label>Fig. 4</label><caption xml:lang="en"><p>Biocompatibility of Bi:Cu<sub>2</sub>O@HA NPs. <bold>A</bold>, <bold>B</bold> Viability of CT26 cells and HUVEC cells incubated with different concentrations of Bi:Cu<sub>2</sub>O@HA for 12 and 24 h, respectively. <bold>C</bold> Hemolytic effect of Bi:Cu<sub>2</sub>O@HA NPs. <bold>D</bold> Hematological assay data of mice before (Control) and after (Bi:Cu<sub>2</sub>O@HA) intravenous administration of Bi:Cu<sub>2</sub>O@HA NPs</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig4_HTML.png"/></fig></p></sec><sec id="Sec7"><title>In vitro PTT</title><p id="Par22">To explore the photothermal effect of Bi:Cu<sub>2</sub>O@HA NPs after triggering by H<sub>2</sub>S, the CT26 cells were stained with Calcein-AM (AM) and propidium iodide (PI) to visualize the therapeutic effect, while the apoptosis rate of the cells was evaluated by flow cytometry. The cells in the PBS, NPs, and NPs + NaHS groups were incubated with PBS, NPs, and NPs + NaHS media, respectively, while the cells in the PBS + laser, NPs + laser, and NPs + NaHS + laser groups were additionally subjected to laser irradiation. First, the CT26 cells were stained with Calcein AM (green, live cells) and propidium iodide (PI; red, dead cells), as illustrated in Fig. <xref rid="Fig5" ref-type="fig">5</xref>A. In the PBS and NPs groups along with the PBS + laser and NPs + laser groups, red fluorescence was negligible, indicating that these treatments did not cause cell death. Although CuS was generated in the NPs + NaHS group, only a few cells were observed with red fluorescence, indicated that the NPs + NaHS treatment could not induce cell death without laser irradiation. In contrast, most cells in the NPs + NaHS + laser group showed red fluorescence, indicating the good photothermal treatment effect of the H<sub>2</sub>S-activated Bi:Cu<sub>2</sub>O@HA NPs under 808-nm laser irradiation. The apoptosis of CT26 cells in different groups was quantified by flow cytometry (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S13). The apoptosis rates of cells in the PBS, PBS + laser, NPs, NPs + laser, NPs + NaHS, and NPs + NaHS + laser groups were 2.96%, 2.50%, 4.12%, 4.30%, 1.70%, and 54.21%, respectively (Fig. <xref rid="Fig5" ref-type="fig">5</xref>B), further indicating that the H<sub>2</sub>S-activated Bi:Cu<sub>2</sub>O@HA NPs effectively induced apoptosis in cancer cells under 808-nm laser irradiation. Next, we studied the in vitro cytotoxic effect of different groups using MTT assay and drawn the same conclusion (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S14). To investigate the photothermal effect of H<sub>2</sub>S-activated Bi:Cu<sub>2</sub>O@HA NPs under 808-nm laser irradiation on cell migration, wound-healing assays were carried out using CT26 colon cancer cells. After scratching, the cells in the PBS, NPs, and NPs + NaHS groups were incubating with PBS, NPs, and NPs + NaHS media for different times, while the PBS + laser, NPs + laser, and NPs + NaHS + laser groups additionally received 5 min of irradiation with an 808-nm laser.</p><p id="Par23"><fig id="Fig5"><label>Fig. 5</label><caption xml:lang="en"><p>In vitro PTT effect. <bold>A</bold> Confocal laser scanning microscopy images of CT26 cells stained by Calcein AM (green color) and PI (red color). <bold>B</bold> Apoptotic indexes for different groups. Data are presented as means ± SDs (n = 3). ****p &lt; 0.0001. <bold>C</bold> Photographs of the scratched areas after treatment in different groups</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig5_HTML.png"/></fig></p><p id="Par24">As shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>C, the CT26 cells in the PBS, NPs, NPs + NaHS, PBS + laser, NPs + laser, and NPs + NaHS groups still showed movement in the scratched area, suggesting that these treatments did not significantly affect the migratory ability of CT26 cells. Compared to the other groups, the cells in the NPs + NaHS + laser group barely moved toward the scratched area, indicating that PTT based on the H<sub>2</sub>S-activated Bi:Cu<sub>2</sub>O@HA NPs under 808-nm laser irradiation will obviously inhibit the migration of CT26 cells (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S15). The above results indicate that PTT based on Bi:Cu<sub>2</sub>O@HA NPs triggered by H<sub>2</sub>S can both promote cell apoptosis and inhibit cell migration. Thus, the Bi:Cu<sub>2</sub>O@HA NPs show promise as a nano-agent for the treatment of colon cancer.</p></sec><sec id="Sec8"><title>In vivo PTT</title><p id="Par25">To confirm the tumor ablation effect of the Bi:Cu<sub>2</sub>O@HA NPs in vivo, experiments were carried out in CT26 tumor-bearing mice. First, the mice in the PBS + laser and NPs + laser groups were intravenously injected with PBS and Bi:Cu<sub>2</sub>O@HA NPs, respectively, while the mice in the NPs + AOAA + laser and NPs + SAM + laser groups were also pretreated with AOAA (aminooxyacetic acid, an endogenous H<sub>2</sub>S inhibitor) and SAM (<italic>S</italic>-adenosyl-L-methionine, an endogenous H<sub>2</sub>S promoter), respectively, before injection with Bi:Cu<sub>2</sub>O@HA NPs. According to the CT imaging results, the Bi:Cu<sub>2</sub>O@HA NPs reached the maximum enrichment level in the tumor at 6 h after injection. Therefore, PTT was performed at 6 h after injection, and the temperature changes in the tumor region were monitored using a thermal camera. As shown in Fig. <xref rid="Fig6" ref-type="fig">6</xref>A and B, the color of the tumor sites in the PBS + laser, NPs + laser, and NPs + AOAA + laser groups did not change obviously after 5 min of laser irradiation, and the temperature increased from 34.75 to 36.8 °C, 39.98 °C, and 38.65 °C, respectively. In contrast, an obvious color change was observed in the NPs + SAM + laser group, and the temperature increased to 47.23 °C. The large difference between the NPs + SAM + laser group and the other groups demonstrates that the photothermal activity of Bi:Cu<sub>2</sub>O@HA was only activated by the endogenous H<sub>2</sub>S in the colon cancer tumor. After laser treatment, a tumor tissue was randomly dissected from each group, and the necrosis and apoptosis in the tumor tissue were evaluated by H&amp;E and TUNEL staining. H&amp;E staining (Fig. <xref rid="Fig6" ref-type="fig">6</xref>C) showed that the tumor tissues in the PBS + laser, NPs + laser, and NPs + AOAA + laser groups were not obviously damaged under laser irradiation. In contrast, a large amount of cell necrosis was observed in the tumors in the NPs + SAM + laser group, and the corresponding positive cell rate was 65.67% (Fig. <xref rid="Fig6" ref-type="fig">6</xref>D). According to the TUNEL staining images (Fig. <xref rid="Fig6" ref-type="fig">6</xref>E), the tumor slices from the PBS + laser, NPs + laser, and NPs + AOAA + laser groups showed almost no green fluorescence (dead cells), indicating that only a small number of cells were apoptotic In contrast, a large area of green fluorescence was observed in the NPs + SAM + laser group, suggesting that the photothermal effect of the activated Bi:Cu<sub>2</sub>O@HA NPs killed cells in vivo. The corresponding cell apoptosis rates in the PBS + laser, NPs + laser and NPs + AOAA + laser, and NPs + SAM + laser groups were 8.86%, 6.54%, 6.98%, and 58.09%, respectively (Fig. <xref rid="Fig6" ref-type="fig">6</xref>F), in agreement with the H&amp;E staining results (Fig. <xref rid="Fig6" ref-type="fig">6</xref>D). The above results demonstrate that the photothermal activity of the Bi:Cu<sub>2</sub>O@HA NPs can be triggered by the overexpressed H<sub>2</sub>S in colon cancer cells, and that the NPs exhibit an excellent photothermal therapeutic effect, suggesting that the NPs are a promising candidate for colon cancer therapy.</p><p id="Par26"><fig id="Fig6"><label>Fig. 6</label><caption xml:lang="en"><p>In vivo PTT. <bold>A</bold>, <bold>B</bold> Thermal images and corresponding temperature changes of the mice in different groups under laser irradiation. <bold>C</bold>, <bold>D</bold> Photographs of H&amp;E-stained global and local tumor slices and the corresponding necrosis rates for different groups. <bold>E</bold>, <bold>F</bold> Fluorescence images of TUNEL-stained global and local tumor slices and the corresponding apoptosis rates for different groups</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig6_HTML.png"/></fig></p><p id="Par27">To evaluate the therapeutic effect of Bi:Cu<sub>2</sub>O@HA NPs in vivo, the state of subsistence and tumor volume of the mice were monitored for 15 d. As demonstrated in Fig. <xref rid="Fig7" ref-type="fig">7</xref>A, the tumors of the mice in the PBS + laser, NPs + laser, and NPs + AOAA + laser groups continued to grow rapidly, while the tumors of the mice completely disappeared after 15 d of treatment (Additional file <xref ref-type="supplementary-material" rid="MOESM1">1</xref>: Figure S16). The corresponding changes in the relative tumor volumes for each group revealed similar results (Fig. <xref rid="Fig7" ref-type="fig">7</xref>B), indicating that only the activated, photothermally active Bi:Cu<sub>2</sub>O@HA NPs could eliminate the tumors. To evaluate the long-term biocompatibility of the Bi:Cu<sub>2</sub>O@HA NPs in vivo, the body weights of the mice in all groups were monitored for 15 d. Subsequently, one of the cured mice in the NPs + SAM + laser group was euthanized, and its main organs were dissected for comparison with those of normal mice to further evaluate the long-term biocompatibility of Bi:Cu<sub>2</sub>O@HA NPs in vivo. As shown in Fig. <xref rid="Fig7" ref-type="fig">7</xref>C, the body weight of the mice did not change significantly during the treatment process, indicating that the Bi:Cu<sub>2</sub>O@HA NPs did not affect the normal life activities of the mice or have obvious toxic or side effects. Notably, in contrast to the normal mice, the H&amp;E-stained sections of the cured mouse showed no obvious signs of tissue necrosis (Fig. <xref rid="Fig7" ref-type="fig">7</xref>D), indicating that the Bi:Cu<sub>2</sub>O@HA NPs have good long-term biocompatibility in vivo. These results suggest that the Bi:Cu<sub>2</sub>O@HA NPs show excellent potential for the PTT of colon cancer.</p><p id="Par28"><fig id="Fig7"><label>Fig. 7</label><caption xml:lang="en"><p>PTT effect in vivo. <bold>A</bold> Images of CT26 tumor-bearing mice collected after 15 days of treatment. <bold>B</bold>, <bold>C</bold> Relative tumor volume and body weights in mice during 15 days of treatment in different groups. Data are presented as means ± SDs (n = 4). ***p &lt; 0.001, ****p &lt; 0.0001. <bold>D</bold> H&amp;E staining images of major organs from normal and cured mice</p></caption><graphic specific-use="web" mime-subtype="PNG" xlink:href="MediaObjects/12951_2022_1555_Fig7_HTML.png"/></fig></p></sec></sec><sec id="Sec9" sec-type="conclusion"><title>Conclusions</title><p id="Par29">In summary, Bi:Cu<sub>2</sub>O@HA NPs, an H<sub>2</sub>S-responsive agent with tumor-targeted delivery and an excellent theranostic effect for colon cancer were successfully prepared via a one-pot method. Doping with Bi not only enhances the NIR absorption of the endogenous H<sub>2</sub>S-triggered Cu<sub>2</sub>O, it also serves as a CT agent for tumor imaging. Moreover, HA can specifically target the CD44 receptors that are overexpressed in colon cancer cells, thereby improving the enrichment of the Bi:Cu<sub>2</sub>O NPs in tumors and enhancing the therapeutic effect. The results demonstrate that the H<sub>2</sub>S-activated Bi:Cu<sub>2</sub>O@HA NPs have a good PTT effect without toxic side effects in healthy tissues during the treatment process. The novel Bi:Cu<sub>2</sub>O@HA NPs with enhanced H<sub>2</sub>S-responsive photothermal performance provide a new strategy for targeted colon cancer therapy.</p></sec><sec id="Sec10" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec11"><title>Chemicals and materials</title><p id="Par30">Bismuth nitrate and hyaluronic acid were purchased from Shanghai McLean Biochemical Technology Co., Ltd. Copper acetate and sodium hydroxide were purchased from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China). Ascorbic acid was purchased from Sigma-Aldrich (St. Louis, MO, USA). Sodium hydrosulfide purchased from Adamas-beta. All chemicals were used directly without further processing.</p></sec><sec id="Sec12"><title>Preparation of Bi:Cu<sub>2</sub>O@HA NPs</title><p id="Par31">First, 70 mg HA and 1.0 mL Bi(NO<sub>3</sub>)<sub>3</sub>·5H<sub>2</sub>O (0.14 M) were mixed in 50 mL of deionized water under stirring. Next, 1.0 mL NaOH (2 M) was added slowly to the above mixture, and 1.4 mL Cu(CH<sub>3</sub>COO)<sub>2</sub> (0.2 M) and 1.0 mL NaOH (2 M) were successively added. Finally, 2.0 mL ascorbic acid (0.1 M) was added, and the mixture was stirred for 10 min. The formed Bi:Cu<sub>2</sub>O@HA NPs were centrifuged to remove excess solvent and washed three times with deionized water.</p></sec><sec id="Sec13"><title>Characterization</title><p id="Par32">The morphology of the Bi:Cu<sub>2</sub>O@HA NPs was determined by SEM (Zeiss EVO MA 26/LS 26) and TEM (JEOL JEM-2100). The crystalline structure of the Bi:Cu<sub>2</sub>O@HA NPs was confirmed by XRD (Rigaku, Tokyo, Japan). The UV-VIS-NIR absorbance spectrum was measured using a spectrophotometer (DU 730: Beckman Coulter, Brea, CA, USA). CT imaging was performed using a PET/CT in vivo molecular and preclinical imager (Mediso, Nanoscan PET/CT 82s, Hungary).</p></sec><sec id="Sec14"><title>H<sub>2</sub>S-responsive performance of the Bi:Cu<sub>2</sub>O@HA NPs</title><p id="Par33">NaHS was used to simulate endogenous H<sub>2</sub>S. After incubation with NaHS (4 mM) at 37 °C for 90 min, the Bi:Cu<sub>2</sub>O@HA NPs (0.5 mM) were centrifuged for SEM and XRD characterization to explore the changes after H<sub>2</sub>S triggering. The absorption of both the Bi:Cu<sub>2</sub>O@HA NPs (40 µg/mL) and Cu<sub>2</sub>O@HA (40 µg/mL) before and after incubation with NaHS (4 mM) at 37 °C for 90 min was evaluated to determine whether doping with Bi enhanced the absorption of endogenous H<sub>2</sub>S-responsive Cu<sub>2</sub>O in the NIR region. Subsequently, a thermal imager (FLIR A300) was used to measure the temperature changes of the Bi:Cu<sub>2</sub>O@HA NPs (40 µg/mL) and Cu<sub>2</sub>O@HA (40 µg/mL) after vulcanization under 808-nm laser irradiation at 1.0 W/cm<sup>2</sup> for 25 min. To demonstrate the remarkable photothermal stability of the H<sub>2</sub>S-activated Bi:Cu<sub>2</sub>O@HA NPs, we exposed the vulcanized liquid to 808-nm (1.0 W/cm<sup>2</sup>) laser irradiation for 25 min and then turned off the laser for 25 min; this heating and cooling process was repeated six times. Throughout the heating and cooling cycles, the temperature of the solution was recorded by a thermal camera (FLIR A300).</p></sec><sec id="Sec15"><title>CT imaging performance of the Bi:Cu<sub>2</sub>O@HA NPs in vitro</title><p id="Par34">To investigate the CT imaging performance of the Bi:Cu<sub>2</sub>O@HA NPs, the same concentrations (1, 2, 4, 6, 8, and 10 mg/mL) of the prepared Bi:Cu<sub>2</sub>O@HA NPs and Iohexol were placed in 2-mL EP tubes for in vitro CT imaging. PBS was used as a control (0 mg/mL).</p></sec><sec id="Sec16"><title>Targeting ability of the Bi:Cu<sub>2</sub>O@HA NPs in vitro</title><p id="Par35">The targeting experiments were divided into two groups: the Bi:Cu<sub>2</sub>O@HA group was treated with 2 mL of Bi:Cu<sub>2</sub>O@HA NPs (0.125, 0.25, 0.5, and 1.0 mg/mL); and the block group was treated with a mixture of 1 mL each of HA and Bi:Cu<sub>2</sub>O@HA NPs (0.25, 0.5, 1.0, 2.0 mg/mL). The two groups were incubated with CT26 cells for 12 h followed by the collection of CT images, respectively. Three wells were set up for each concentration, and DMEM high-glucose medium was used as a control (0 mg/mL).</p></sec><sec id="Sec17"><title>Biocompatibility of the Bi:Cu<sub>2</sub>O@HA NPs</title><p id="Par36">Cytotoxicity assay: The CT26 cells were first incubated with DMEM (control) or a Bi:Cu<sub>2</sub>O@HA DMEM dispersion with a concentration of 5, 10, 20, 40, or 60 µg/mL for 12 or 24 h. Next, 10 µL of MTT was added and cultured in a cell incubator for 4 h. Subsequently, 100 µL of formazan solution was added to the well and cultured in the cell incubator for another 4 h. Finally, the absorbance at 570 nm was measured using a microplate reader. Five parallel groups were set up for each concentration.</p><p id="Par37">Hemolysis test: A suspension of red blood cells in PBS (0.4 mL, 2%) was prepared following a previous report [<xref ref-type="bibr" rid="CR39">39</xref>] and added into 1 mL of PBS buffer solution (negative group), deionized water (positive group), or a Bi:Cu<sub>2</sub>O@HA NPs PBS dispersion with a concentration of 5, 10, 20, 40, or 60 µg/mL. After 4 h, the mixture was centrifuged, and the absorbance of the supernatant in each group was measured at 541 nm. The hemolysis rate was calculated following a previous report [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. Three parallel samples were established in each group.</p><p id="Par38">Routine blood analysis: The mice were randomly divided into two groups with three mice per group. One group was intravenously injected with PBS (100 µL), while the other group was injected with 100 µL Bi:Cu<sub>2</sub>O@HA (10 mg/kg). After 36 h, the blood was collected for routine blood analysis.</p></sec><sec id="Sec18"><title>In vitro PTT with Bi:Cu<sub>2</sub>O@HA NPs</title><p id="Par39">The grouping and treatment of cells were the same for all three assays to investigate the photothermal effect of the Bi:Cu<sub>2</sub>O@HA NPs. Namely, the groups were the PBS, PBS + laser, NPs, NPs + laser, NPs + NaHS, and NPs + NaHS + laser groups. The cells in the PBS, NPs, and NPs + NaHS group were incubated with DMEM, Bi:Cu<sub>2</sub>O@HA NPs, and Bi:Cu<sub>2</sub>O@HA NPs + NaHS, respectively. The laser groups additionally received irradiation with an 808-nm laser at 1 W/cm<sup>2</sup> for 5 min. The concentrations of Bi:Cu<sub>2</sub>O@HA and NaHS in the NPs, NPs + laser, NPs + NaHS, and NPs + NaHS + laser groups were both 0.4 mM.</p><p id="Par40">Calcein-AM/PI double-staining assay: The cells were incubated in six-well plates. After 6 h of treatment, the medium solution in the well was removed and washed with PBS. The cells were then stained by Calcein AM-PI work solution (5 mL of PBS with 10 µL of Calcein-AM and 15 µL of PI). After 15 min, the AM-PI work solution in the well was removed and washed by DMEM for observation by confocal laser scanning microscopy.</p><p id="Par41">Flow cytometry assay: The cells were incubated in six-well plates. After 6 h of treatment, the cells were collected in a centrifuge tube by digestion for staining using the staining solution (100 µL 1 × buffer with 5 µL FITC and 5 µL PI). After staining, the cells were transferred into a flow tube with a strainer for flow cytometry using Novocyte 2000 (Agilent).</p><p id="Par42">Wound-healing assay: The cells were incubated in six-well plates. Before treatment, one clear line was scratched, and a photograph was taken in each group for use as a control. After 6 h of treatment, the culture medium was removed and washed with PBS to eliminate floating cells. The scratched line was recorded by taking a photograph using the same scale as for the control. The medium was then replaced with fresh medium for the next 6 h of incubation. The above steps were repeated to collect photographs of the scratched line after 6, 12, and 24 h of incubation in each group.</p><p id="Par43">In vitro toxicity assay: Cells were cultured overnight in 96-well plates. After 6 h of treatment in different groups, 10 µL of MTT solution was added to each well to continue culturing cells for 4 h. After that, dimethyl sulfoxide (100 µL) was added and shaken gently to dissolve the crystals. Measure the absorbance of the solution at 570 nm on a microplate reader.</p></sec><sec id="Sec19"><title>Tumor models</title><p id="Par44">Female mice aged 5–6 weeks old were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. The CT26 tumor-bearing mouse model was established by subcutaneously injecting 1 × 10<sup>6</sup> CT26 tumor cell suspension into the right upper limb of each mouse. When the tumor volume reached 100 mm<sup>3</sup>, follow-up experiments were started in the mice.</p></sec><sec id="Sec20"><title>In vivo targeting and CT imaging performance of Bi:Cu<sub>2</sub>O@HA</title><p id="Par45">The CT26 tumor-bearing mice were randomly divided into two groups: the Bi:Cu<sub>2</sub>O@HA group was intravenously injected with Bi:Cu<sub>2</sub>O@HA NPs (10 mg/kg), while the block group was first intravenously injected with HA (50 µL, 1 mg/mL) followed by the intravenous injection of Bi:Cu<sub>2</sub>O@HA NPs (10 mg/kg) half an hour later. The CT images of the mice were collected before injection (control) and at 0.5, 2, 4, 6, 8, 12, and 24 h after injection.</p></sec><sec id="Sec21"><title>In vivo photothermal imaging and PTT</title><p id="Par46">The CT26 tumor-bearing mice were randomly divided into four groups (PBS + laser, NPs + laser, NPs + AOAA + laser, and NPs + SAM + laser) with five mice in each group. For the PBS + laser and NPs + laser groups, the mice were injected with PBS (100 µL) and Bi:Cu<sub>2</sub>O@HA NPs (10 mg/kg), respectively. The mice in the NPs + AOAA + laser and NPs + SAM + laser groups were first injected with AOAA (100 µL, 0.5 mg/mL) and SAM (100 µL, 5 mg/mL) in the abdominal cavity and then injected with Bi:Cu<sub>2</sub>O@HA NPs (10 mg/kg) after 12 h. At 6 h after each injection, the tumor was irradiated with an 808-nm laser (1 W/cm<sup>2</sup>) for 5 min. A thermal imaging camera was used to record the photothermal images in the different groups. Finally, one mouse was randomly selected from each group, and the tumor tissue was dissected for H&amp;E and TUNEL staining after the photothermal treatment. For the remaining groups of mice (<italic>n</italic> = 4), the body weights and tumor volumes were recorded over 15 d.</p></sec></sec></body><back><ack><title>Acknowledgements</title><p>We thank the Instrument Analysis Center of Shanghai University of Medicine and Health Sciences and Shanghai Normal University for material testing.</p></ack><sec sec-type="author-contribution"><title>Author contributions</title><p>QT and GH designed the experiments. YC, HB and RQ conducted the experiments and obtained the results. RQ and FC participated in the in vivo experiments. FX and LA contributed to the data analysis. YC, HB, FX and QT contributed to the manuscript preparation. All authors read and approved the final manuscript. YC and HB contributed equally.</p></sec><sec><title>Funding</title><p>This work was partially supported by Natural Science Foundation of Shanghai (20ZR1472300, 21ZR1428500), the Key Program of National Natural Science Foundation of China (Grant No.81830052), Foundation of National Infrastructures for Translational Medicine (Shanghai, TMSK-2021-131), and Construction project of Shanghai Key Laboratory of Molecular Imaging (18DZ2260400).</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analyzed during this study are included in this article.</p></sec><sec sec-type="ethics-statement"><title>Declarations</title><sec id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par47">The mouse experiments were conducted in strict accordance with the standards of the SLAC Institutional Animal Care and Use Committee and were approved by the Animal Ethics Committee of Shanghai University of Medicine and Health Sciences.</p></sec><sec id="FPar2"><title>Consent for publication</title><p id="Par48">All authors agree to be published.</p></sec><sec id="FPar3" sec-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare no competing financial interest.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>E-K</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Paik</surname><given-names>S</given-names></name><name><surname>Haam</surname><given-names>S</given-names></name><name><surname>Huh</surname><given-names>Y-M</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Nanomaterials for theranostics: recent advances and future challenges</article-title><source>Chem Rev</source><year>2015</year><volume>115</volume><fpage>327</fpage><lpage>94</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhvFOhtrrE</pub-id><pub-id pub-id-type="doi">10.1021/cr300213b</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhen</surname><given-names>X</given-names></name><name><surname>Upputuri</surname><given-names>PK</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Pramanik</surname><given-names>M</given-names></name><name><surname>Pu</surname><given-names>K</given-names></name><name><surname>Xing</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Redox-activatable and acid-enhanced nanotheranostics for second near-infrared photoacoustic tomography and combined photothermal tumor therapy</article-title><source>ACS Nano</source><year>2019</year><volume>13</volume><fpage>5816</fpage><lpage>25</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXosVeju7k%3D</pub-id><pub-id pub-id-type="doi">10.1021/acsnano.9b01411</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">Intracellular mutual amplification of oxidative stress and inhibition multidrug resistance for enhanced sonodynamic/chemodynamic/chemo therapy</article-title><source>Small</source><year>2022</year><volume>18</volume><fpage>2107160</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB38XjsFCms7k%3D</pub-id><pub-id pub-id-type="doi">10.1002/smll.202107160</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>H-F</given-names></name><name><surname>Hou</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hui</surname><given-names>Y</given-names></name><name><surname>Petrovsky</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>C-X</given-names></name></person-group><article-title xml:lang="en">A microfluidic tumor-on-a-chip for assessing multifunctional liposomes’ tumor targeting and anticancer efficacy</article-title><source>Advanced Healthcare Materials</source><year>2019</year><volume>8</volume><fpage>1900015</fpage><pub-id pub-id-type="doi">10.1002/adhm.201900015</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Ishigaki</surname><given-names>Y</given-names></name><name><surname>Pu</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>H-Y</given-names></name><name><surname>Ye</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Engineering of electrochromic materials as activatable probes for molecular imaging and photodynamic therapy</article-title><source>J Am Chem Soc</source><year>2018</year><volume>140</volume><fpage>16340</fpage><lpage>52</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXitVyju77E</pub-id><pub-id pub-id-type="pmid">30384600</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Yue</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Bu</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Inhibition of hydrogen sulfide synthesis reverses acquired resistance to 5-FU through miR-215-5p-EREG/TYMS axis in colon cancer cells</article-title><source>Cancer Lett</source><year>2019</year><volume>466</volume><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXhvVyltrjN</pub-id><pub-id pub-id-type="doi">10.1016/j.canlet.2019.09.006</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashfi</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">The role of hydrogen sulfide in health and disease</article-title><source>Biochem Pharmacol</source><year>2018</year><volume>149</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXjslOhtbw%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.bcp.2018.02.030</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papapetropoulos</surname><given-names>A</given-names></name><name><surname>Pyriochou</surname><given-names>A</given-names></name><name><surname>Altaany</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Marazioti</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Jeschke</surname><given-names>MG</given-names></name><name><surname>Branski</surname><given-names>LK</given-names></name><name><surname>Herndon</surname><given-names>DN</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Szabó</surname><given-names>C</given-names></name></person-group><article-title xml:lang="en">Hydrogen sulfide is an endogenous stimulator of angiogenesis</article-title><source>Proc Natl Acad Sci.</source><year>2009</year><volume>106</volume><fpage>21972</fpage><lpage>77</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXlt1Wmug%3D%3D</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0908047106</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>C</given-names></name><name><surname>Coletta</surname><given-names>C</given-names></name><name><surname>Chao</surname><given-names>C</given-names></name><name><surname>Módis</surname><given-names>K</given-names></name><name><surname>Szczesny</surname><given-names>B</given-names></name><name><surname>Papapetropoulos</surname><given-names>A</given-names></name><name><surname>Hellmich</surname><given-names>MR</given-names></name></person-group><article-title xml:lang="en">Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer</article-title><source>Proc Natl Acad Sci.</source><year>2013</year><volume>110</volume><fpage>12474</fpage><lpage>79</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXht1emu7bL</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1306241110</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Activatable nanoscale metal-organic framework for ratiometric photoacoustic imaging of hydrogen sulfide and orthotopic colorectal cancer in vivo</article-title><source>Sci China Chem</source><year>2020</year><volume>63</volume><fpage>1315</fpage><lpage>22</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXhtF2jurnF</pub-id><pub-id pub-id-type="doi">10.1007/s11426-020-9775-y</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>Y-Y</given-names></name><name><surname>Fan</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z-S</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name></person-group><article-title xml:lang="en">A multifunctional BODIPY based fluorescent probe for hydrogen sulfide detection and photodynamic anticancer therapy in HCT116 colon cancer cell</article-title><source>Dyes Pigments</source><year>2022</year><volume>197</volume><fpage>109897</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXitlWktrnK</pub-id><pub-id pub-id-type="doi">10.1016/j.dyepig.2021.109897</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>C</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Surface plasmon resonance–enhanced photoacoustic imaging and photothermal therapy of endogenous H<sub>2</sub>S-triggered Au@Cu<sub>2</sub>O</article-title><source>Small</source><year>2019</year><volume>15</volume><fpage>1903473</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXhslOgsrrN</pub-id><pub-id pub-id-type="doi">10.1002/smll.201903473</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>J</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect</article-title><source>Adv Drug Deliv Rev</source><year>2011</year><volume>63</volume><fpage>136</fpage><lpage>51</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXktF2jur8%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.addr.2010.04.009</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>J</given-names></name></person-group><article-title xml:lang="en">The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo</article-title><source>Adv Drug Deliv Rev</source><year>2013</year><volume>65</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38Xhs1CjsbnI</pub-id><pub-id pub-id-type="doi">10.1016/j.addr.2012.10.002</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabin</surname><given-names>O</given-names></name><name><surname>Manuel Perez</surname><given-names>J</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Wojtkiewicz</surname><given-names>G</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles</article-title><source>Nat Mater</source><year>2006</year><volume>5</volume><fpage>118</fpage><lpage>22</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD28XptFOgsg%3D%3D</pub-id><pub-id pub-id-type="doi">10.1038/nmat1571</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Large-scale synthesis of Bi<sub>2</sub>S<sub>3</sub> nanodots as a contrast agent for in vivo X-ray computed tomography imaging</article-title><source>Adv Mater</source><year>2011</year><volume>23</volume><fpage>4886</fpage><lpage>91</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXht1Cjs7%2FL</pub-id><pub-id pub-id-type="doi">10.1002/adma.201103289</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>M-H</given-names></name><name><surname>Ma</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>X-Q</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>H-X</given-names></name><name><surname>Chen</surname><given-names>H-R</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name></person-group><article-title xml:lang="en">Multifunctional Bi<sub>2</sub>S<sub>3</sub>/PLGA nanocapsule for combined HIFU/radiation therapy</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><fpage>8197</fpage><lpage>205</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhtVGqu7rJ</pub-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.06.010</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malakooti</surname><given-names>R</given-names></name><name><surname>Cademartiri</surname><given-names>L</given-names></name><name><surname>Akçakir</surname><given-names>Y</given-names></name><name><surname>Petrov</surname><given-names>S</given-names></name><name><surname>Migliori</surname><given-names>A</given-names></name><name><surname>Ozin</surname><given-names>GA</given-names></name></person-group><article-title xml:lang="en">Shape-controlled Bi<sub>2</sub>S<sub>3</sub> nanocrystals and their plasma polymerization into flexible films</article-title><source>Adv Mater</source><year>2006</year><volume>18</volume><fpage>2189</fpage><lpage>94</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD28XptlygsbY%3D</pub-id><pub-id pub-id-type="doi">10.1002/adma.200600460</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>L</given-names></name><name><surname>Bernechea</surname><given-names>M</given-names></name><name><surname>de Arquer</surname><given-names>FPG</given-names></name><name><surname>Konstantatos</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Near IR-sensitive, non-toxic, polymer/nanocrystal solar cells employing Bi<sub>2</sub>S<sub>3</sub> as the electron acceptor</article-title><source>Adv Energy Mater</source><year>2011</year><volume>1</volume><fpage>1029</fpage><lpage>35</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3MXhsFyqsLfF</pub-id><pub-id pub-id-type="doi">10.1002/aenm.201100441</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigman</surname><given-names>MB</given-names></name><name><surname>Korgel</surname><given-names>BA</given-names></name></person-group><article-title xml:lang="en">Solventless synthesis of Bi<sub>2</sub>S<sub>3</sub> (Bismuthinite) nanorods, nanowires, and nanofabric</article-title><source>Chem Mater</source><year>2005</year><volume>17</volume><fpage>1655</fpage><lpage>60</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BD2MXhsl2ru7c%3D</pub-id><pub-id pub-id-type="doi">10.1021/cm0478733</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>JW</given-names></name><name><surname>Lawson</surname><given-names>G</given-names></name><name><surname>O’Brien</surname><given-names>P</given-names></name><name><surname>Klenkler</surname><given-names>R</given-names></name><name><surname>Helander</surname><given-names>MG</given-names></name><name><surname>Petrov</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>Z-H</given-names></name><name><surname>Kherani</surname><given-names>NP</given-names></name><name><surname>Adronov</surname><given-names>A</given-names></name><name><surname>Ozin</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Flash nano-welding: investigation and control of the photothermal response of ultrathin bismuth sulfide nanowire films</article-title><source>Adv Mater</source><year>2010</year><volume>22</volume><fpage>4395</fpage><lpage>400</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3cXhtlSmsrfP</pub-id><pub-id pub-id-type="doi">10.1002/adma.201001349</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Architecting Z-scheme Bi<sub>2</sub>S<sub>3</sub>@CoO with 3D chrysanthemums-like architecture for both photoeletro-oxidization and -reduction performance under visible light</article-title><source>Chem Eng J</source><year>2019</year><volume>378</volume><fpage>122092</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXhtlalsrvL</pub-id><pub-id pub-id-type="doi">10.1016/j.cej.2019.122092</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">A one-pot synthesis of multifunctional Bi<sub>2</sub>S<sub>3</sub> nanoparticles and the construction of core–shell Bi<sub>2</sub>S<sub>3</sub>@Ce6–CeO<sub>2</sub> nanocomposites for NIR-triggered phototherapy</article-title><source>J Mater Chem B</source><year>2020</year><volume>8</volume><fpage>4093</fpage><lpage>105</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXltlCktrc%3D</pub-id><pub-id pub-id-type="doi">10.1039/D0TB00080A</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Sheng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">Fabrication of Cu<sub>2</sub>O/Bi<sub>2</sub>S<sub>3</sub> heterojunction photocatalysts with enhanced visible light photocatalytic mechanism and degradation pathways of tetracycline</article-title><source>J Mol Struct</source><year>2021</year><volume>1229</volume><fpage>129581</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3cXitlWnsbrL</pub-id><pub-id pub-id-type="doi">10.1016/j.molstruc.2020.129581</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>S</given-names></name><name><surname>Bahadur</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">Modified hyaluronic acid based materials for biomedical applications</article-title><source>Int J Biol Macromol</source><year>2019</year><volume>121</volume><fpage>556</fpage><lpage>71</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXhvFChurfL</pub-id><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.10.049</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Activatable hyaluronic acid nanoparticle as a theranostic agent for optical/photoacoustic image-guided photothermal therapy</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>12250</fpage><lpage>58</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhvFaqu7fN</pub-id><pub-id pub-id-type="doi">10.1021/nn506130t</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luan</surname><given-names>Y</given-names></name></person-group><article-title xml:lang="en">A versatile prodrug strategy to in situ encapsulate drugs in MOF nanocarriers: a case of cytarabine-IR820 prodrug encapsulated ZIF-8 toward chemo-photothermal therapy</article-title><source>Adv Funct Mater</source><year>2018</year><volume>28</volume><fpage>1802830</fpage><pub-id pub-id-type="doi">10.1002/adfm.201802830</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Tian</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title xml:lang="en">Nanotubes-embedded indocyanine green–hyaluronic acid nanoparticles for photoacoustic-imaging-guided phototherapy</article-title><source>ACS Appl Mater Interfaces</source><year>2016</year><volume>8</volume><fpage>5608</fpage><lpage>17</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28Xitleqt7g%3D</pub-id><pub-id pub-id-type="doi">10.1021/acsami.5b12400</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>KY</given-names></name><name><surname>Jeon</surname><given-names>EJ</given-names></name><name><surname>Yoon</surname><given-names>HY</given-names></name><name><surname>Lee</surname><given-names>BS</given-names></name><name><surname>Na</surname><given-names>JH</given-names></name><name><surname>Min</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Myung</surname><given-names>S-J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title xml:lang="en">Theranostic nanoparticles based on PEGylated hyaluronic acid for the diagnosis, therapy and monitoring of colon cancer</article-title><source>Biomaterials</source><year>2012</year><volume>33</volume><fpage>6186</fpage><lpage>93</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38Xot12ksLw%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.05.029</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><etal/></person-group><article-title xml:lang="en">pH-responsive core-shell nanogels induce in situ antigen production for cancer treatment</article-title><source>Chem Eng J</source><year>2021</year><volume>426</volume><fpage>130839</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhtl2jt7nF</pub-id><pub-id pub-id-type="doi">10.1016/j.cej.2021.130839</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Han</surname><given-names>MK</given-names></name><name><surname>Viennois</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Si</surname><given-names>X</given-names></name><name><surname>Merlin</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy</article-title><source>Nanoscale</source><year>2015</year><volume>7</volume><fpage>17745</fpage><lpage>55</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXhs1SitbbE</pub-id><pub-id pub-id-type="doi">10.1039/C5NR04831A</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattheolabakis</surname><given-names>G</given-names></name><name><surname>Milane</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Amiji</surname><given-names>MM</given-names></name></person-group><article-title xml:lang="en">Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine</article-title><source>J Drug Target</source><year>2015</year><volume>23</volume><fpage>605</fpage><lpage>18</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXhslWgs7%2FN</pub-id><pub-id pub-id-type="doi">10.3109/1061186X.2015.1052072</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mero</surname><given-names>A</given-names></name><name><surname>Pasqualin</surname><given-names>M</given-names></name><name><surname>Campisi</surname><given-names>M</given-names></name><name><surname>Renier</surname><given-names>D</given-names></name><name><surname>Pasut</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Conjugation of hyaluronan to proteins</article-title><source>Carbohydr Polym</source><year>2013</year><volume>92</volume><fpage>2163</fpage><lpage>70</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC3sXisVSktrs%3D</pub-id><pub-id pub-id-type="doi">10.1016/j.carbpol.2012.11.090</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>H-X</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Y-Y</given-names></name></person-group><article-title xml:lang="en">Hyaluronic-acid-assisted facile synthesis of MnWO<sub>4</sub> single-nanoparticle for efficient trimodal imaging and liver–renal structure display</article-title><source>ACS Appl Nano Mater</source><year>2018</year><volume>1</volume><fpage>101</fpage><lpage>10</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2sXhvFCktLrI</pub-id><pub-id pub-id-type="doi">10.1021/acsanm.7b00047</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattheolabakis</surname><given-names>G</given-names></name><name><surname>Rigas</surname><given-names>B</given-names></name><name><surname>Constantinides</surname><given-names>PP</given-names></name></person-group><article-title xml:lang="en">Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives</article-title><source>Nanomedicine (Lond)</source><year>2012</year><volume>7</volume><fpage>1577</fpage><lpage>90</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC38Xhs1GlsLnK</pub-id><pub-id pub-id-type="doi">10.2217/nnm.12.128</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Kong</surname><given-names>WH</given-names></name><name><surname>Sung</surname><given-names>DK</given-names></name><name><surname>Lee</surname><given-names>M-Y</given-names></name><name><surname>Beack</surname><given-names>SE</given-names></name><name><surname>Keum</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>KS</given-names></name><name><surname>Yun</surname><given-names>SH</given-names></name><name><surname>Hahn</surname><given-names>SK</given-names></name></person-group><article-title xml:lang="en">Nanographene oxide–hyaluronic acid conjugate for photothermal ablation therapy of skin cancer</article-title><source>ACS Nano</source><year>2014</year><volume>8</volume><fpage>260</fpage><lpage>68</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2cXhvVWqtQ%3D%3D</pub-id><pub-id pub-id-type="doi">10.1021/nn405383a</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name></person-group><article-title xml:lang="en">Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy</article-title><source>Mater Sci Eng C</source><year>2020</year><volume>106</volume><fpage>110100</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1MXhslGntb3F</pub-id><pub-id pub-id-type="doi">10.1016/j.msec.2019.110100</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Rui</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name><name><surname>Tao</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">The insitu sulfidation of Cu<sub>2</sub>O by endogenous H<sub>2</sub>S for colon cancer theranostics</article-title><source>Angew Chem Int Edn</source><year>2018</year><volume>57</volume><fpage>15782</fpage><lpage>86</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC1cXitFeisL7F</pub-id><pub-id pub-id-type="doi">10.1002/anie.201810082</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>An</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Tian</surname><given-names>Q</given-names></name></person-group><article-title xml:lang="en">Remodeling endogenous H<sub>2</sub>S microenvironment in colon cancer to enhance chemodynamic therapy</article-title><source>Chem Eng J</source><year>2021</year><volume>422</volume><fpage>130098</fpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BB3MXhtVeiu7jL</pub-id><pub-id pub-id-type="doi">10.1016/j.cej.2021.130098</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">Core–shell MnSe@Bi<sub>2</sub>Se<sub>3</sub> fabricated via a cation exchange method as novel nanotheranostics for multimodal imaging and synergistic thermoradiotherapy</article-title><source>Adv Mater</source><year>2015</year><volume>27</volume><fpage>6110</fpage><lpage>17</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC2MXhsVOnu7nK</pub-id><pub-id pub-id-type="doi">10.1002/adma.201503006</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>G</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Yi</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title xml:lang="en">Perfluorocarbon-loaded hollow Bi<sub>2</sub>Se<sub>3</sub> nanoparticles for timely supply of oxygen under near-infrared light to enhance the radiotherapy of cancer</article-title><source>Adv Mater</source><year>2016</year><volume>28</volume><fpage>2716</fpage><lpage>23</lpage><pub-id pub-id-type="other" assigning-authority="ChemPort ( Chemical Abstract Service )">1:CAS:528:DC%2BC28Xit1OjtL8%3D</pub-id><pub-id pub-id-type="doi">10.1002/adma.201504617</pub-id></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1" specific-use="web-only"><sec id="Sec22"><title>Supplementary Information</title><p id="Par50"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary Information"><media mimetype="application" mime-subtype="msword" xlink:href="MediaObjects/12951_2022_1555_MOESM1_ESM.docx" position="anchor"><caption xml:lang="en"><p><bold>Additional file 1: Figure S1</bold>. Size statistics of the Bi:Cu<sub>2</sub>O@HA NPs in a SEM image. <bold>Figure S2.</bold> XPS spectrum of the Bi:Cu<sub>2</sub>O@HA NPs. <bold>Figure S3.</bold> EDX analysis spectrum of the Bi:Cu<sub>2</sub>O@HA NPs. <bold>Figure S4.</bold> Zeta potentials of Cu<sub>2</sub>O@HA NPs and Bi:Cu<sub>2</sub>O@HA NPs. <bold>Figure S5.</bold> (A) Physiological stability of Bi:Cu<sub>2</sub>O@HA NPs in water. (B) Physiological stability of Bi:Cu<sub>2</sub>O@HA NPs in PBS. (C) Physiological stability of Bi:Cu<sub>2</sub>O@HA NPs in serum. (D) Corrsponding PDI change within 7 days. <bold>Figure S6.</bold> SEM of the Cu<sub>2</sub>O@HA NPs. <bold>Figure S7.</bold> DLS size distributions of the Cu<sub>2</sub>O@HA NPs. <bold>Figure S8.</bold> XRD pattern of Cu<sub>2</sub>O@HA (red line). <bold>Figure S9.</bold> FT-IR spectra of HA (black line) and Cu<sub>2</sub>O@HA NPs (red line). <bold>Figure S10.</bold> (A) UV-vis spectra of Bi:Cu<sub>2</sub>O@HA NPs reacted with NaHS for different time periods. (B) Corresponding absorption values at 808 nm. <bold>Figure S11.</bold> (A) Thermal images of the reaction of 4 mM NaHS with different concentrations of Bi:Cu<sub>2</sub>O@HA NPs (808 nm, 1 W/cm<sup>2</sup>). (B) Thermal images of the reaction of 4 mM NaHA with 0.5 mM Bi:Cu<sub>2</sub>O@HA NPs under different power density. (C) Plots of Δ<italic>T</italic> vs. time for different concentrations Bi:Cu<sub>2</sub>O@HA NPs reacted with 4 mM NaHS (808 nm, 1 W/cm<sup>2</sup>). (D) Plots of Δ<italic>T</italic> vs. time for 0.5 mM Bi:Cu<sub>2</sub>O@HA NPs reacted with 4 mM NaHS under different laser power densities. <bold>Figure S12.</bold> (A) Heating and cooling curves of water and Bi:Cu<sub>2</sub>O@HA + NaHS (4 mM) with the laser on and off. (B) corresponding time constant of the cooling curve. (The photothermal conversion efficiency of Bi:Cu<sub>2</sub>O@HA after reacted with NaHS was calculated to be 16.96%.) <bold>Figure S13.</bold> Apoptosis in CT26 cells after treatment in different groups. <bold>Figure S14.</bold> The cell viability of CT26 after treatment in different groups. Data are presented as means ± SDs (n = 5). ****p &lt; 0.0001. <bold>Figure S15.</bold> Cell migration rate of CT26 cells after treatment in different groups for 6 h, 12 and 24 h. <bold>Figure S16.</bold> Photos of the tumors from mice in different groups after treatment.</p></caption></media></supplementary-material></p></sec></app></app-group><notes notes-type="Misc"><title>Publisher’s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Biotechnology</facet-value><facet-value count="1">Chemistry</facet-value><facet-value count="1">Molecular Medicine</facet-value><facet-value count="1">Nanotechnology</facet-value></facet><facet name="keyword"><facet-value count="1">Colon cancer</facet-value><facet-value count="1">CT imaging</facet-value><facet-value count="1">Cu2O</facet-value><facet-value count="1">Endogenous hydrogen sulfide</facet-value><facet-value count="1">Photothermal therapy</facet-value></facet><facet name="pub"><facet-value count="1">Journal of Nanobiotechnology</facet-value></facet><facet name="year"><facet-value count="1">2022</facet-value></facet><facet name="country"><facet-value count="1">China</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
